checkmate-227: nivolumab ipilimumab in mnsclc
Published 6 years ago • 236 plays • Length 5:31Download video MP4
Download video MP3
Similar videos
-
6:13
checkmate-227: testing ipilimumab/nivolumab in nsclc
-
2:44
cancer immunotherapy with nivolumab plus ipilimumab vs. chemotherapy: insights from checkmate 227
-
5:51
checkmate-227 and the role of tmb in nsclc
-
6:07
interpreting the results of checkmate-227 in nsclc
-
4:47
checkmate 227: combining ctla-4 and pd-l1 in nsclc
-
17:08
three-year update from the checkmate 227 clinical trial for advanced nsclc
-
9:40
asco 2018 - checkmate 227 - combinations of nivolumab and ipilimumab, or nivolumab and and chemo
-
2:33
checkmate 227: chemo-free nsclc treatment
-
5:51
nsclc: use of tmb in checkmate-227
-
1:29
dr. kelly on the toxicity profile in checkmate-227 in nsclc
-
5:13
checkmate-227 regimen safety profile
-
0:50
checkmate 227 induced manageable toxicities with immunotherapy combination in nsclc
-
2:17
dr. borghaei on the checkmate-227 trial in nsclc
-
0:39
dr. lopes on the fda approval of nivolumab/ipilimumab in nsclc
-
6:03
checkmate 9la: nivolumab, ipilimumab and chemotherapy for stage iv nsclc
-
3:04
checkmate 227: final analysis for the non small cell lung cancer trial
-
5:25
dual checkpoint inhibition in nsclc: checkmate-227
-
9:40
are tmb and nivolumab/ipilimumab ready for clinical use? insights from checkmate 227 (bmic-035)
-
10:02
unresectable nsclc - does checkmate 227's suggestion of an immunotherapy combination of yervoy and o